Immunotherapy (Issue 1) | Special Reports

Immunotherapy—An Increasingly Important Role in Oncology

November 21, 2013

Clinical Articles

The use of cancer immunotherapies has evolved. The latest immunotherapies are not only effective, but also accessible enough to be administered not just by expert immunologists, but by general oncologists.

Suzanne Topalian, MD, on PD-1 Targeted Therapy

November 21, 2013

Clinical Articles

Targeted Therapies spoke with Suzanne Topalian, MD, professor of Surgery and Oncology at Johns Hopkins University School of Medicine, about the progress and promise of PD-1 targeted cancer therapy.

A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma

November 21, 2013

Clinical Articles

T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.

MPDL3280A Induces Durable Responses in NSCLC, Other Cancers

November 21, 2013

Clinical Articles

MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.

Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhD

November 20, 2013

Clinical Articles

Targeted Oncology spoke with Antoni Ribas, MD, PhD, director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, about the emerging role for immunotherapy in cancer.

PD-1 and PD-L1 Antibodies in Lung Cancer

November 20, 2013

Clinical Articles

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Nivolumab Plus Ipilimumab in Advanced Melanoma

November 20, 2013

Clinical Articles

Concurrent nivolumab and ipilimumab produced “rapid and deep” responses in patients with advanced melanoma who took part in the first phase I trial to evaluate the PD-1-blocking antibody nivolumab, along with the CTLA-4-blocking antibody ipilimumab.

The Outlook for Immunotherapies

November 19, 2013

Clinical Articles

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.